Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft

Cytokine. 1996 Apr;8(4):330-3. doi: 10.1006/cyto.1996.0045.

Abstract

The combination of Tumour Necrosis Factor (TNF) and mitoxantrone was evaluated for potential chemotherapeutic effect against a human ovarian cancer cell line A2774 hetero-transplanted in female nude mice. Both antitumour efficacy (relative survival and reduction of ascites) and toxicity (weight loss and liver toxicity) of TNF alone, mitoxantrone alone or TNF + mitoxantrone were evaluated. A significant difference (P < 0.002) was observed only among animals bearing tumours treated with mitoxantrone (0.012 mg/Kg) + TNF (5 x 10(5) U/Kg) and controls. No cytotoxic effects were observed for this combination. These observations provide a rationale for further evaluation of TNF + mitoxantrone based regimes for the treatment of recurrent ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Drug Synergism
  • Female
  • Humans
  • Lethal Dose 50
  • Mice
  • Mice, Nude
  • Mitoxantrone / therapeutic use
  • Ovarian Neoplasms / drug therapy*
  • Recombinant Proteins / therapeutic use
  • Transplantation, Heterologous
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Mitoxantrone